New combo shot and pill aims to tame tough leukemia
NCT ID NCT07178912
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests whether giving two drugs together—blinatumomab as a shot under the skin and olverembatinib as a pill—can help control a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). About 60 adults with newly diagnosed or returning disease will take part. The goal is to see if the combination is safe and keeps the cancer in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE II CLINICAL TRIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.